National Comprehensive Cancer Network



About NCCN

NCCN Flash Update: NCCN Guidelines Updated

Flash Update Sent July 25, 2011

NCCN has published updates to the NCCN Guidelines and the NCCN Drugs & Biologics Compendium (NCCN Compendium™) for Antiemesis. These NCCN Guidelines are currently available as Version 1.2012.

Updates to the Guidelines include:

  • AE-2
    High emetic risk intravenous chemotherapy - acute and delayed emesis prevention, added preferred to palonosetron 0.25 mg IV day 1.

  • AE-3
    Moderate emetic risk intravenous chemotherapy - emesis prevention, added preferred to palonosetron 0.25 mg IV day 1 with the following footnote "Data with palonosetron is based on randomized studies with 2 drug combinations."
  • Emetogenic Potential of intravenious Antineoplastic Agents (pages AE-7,-8, and -9) modified footnote t: "Potential drug interactions between antineoplastic agents / antiemetic therapies and various other drugs should always be considered."

  • AE-8
    Low emetogenic potential, added eribulin.
    Minimal emetogenic potential, added ipilimumab and ofatumumab.

  • AE-9
    Minimal to low emetogenic potential, added vandetanib.

The discussion section of the NCCN Guidelines for Antiemesis has been updated to correspond with the treatment algorithm.

For the complete updated version of these and all NCCN Guidelines, visit NCCN.org.

 

 

Quick Links


About NCCN| NCCN Member Institutions| Patient Resources| NCCN Foundation| Privacy Policy| Legal Notices| Contact Us

275 Commerce Drive, Suite 300, Fort Washington, PA 19034 • 215.690.0300 • Fax: 215.690.0280
Copyright © 2013 National Comprehensive Cancer Network, All Rights Reserved